(Reuters) – Japan’s Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients. Vical’s shares was down about 18 percent in light premarket trading on Monday. The DNA vaccine, ASP0113, is designed to prevent cytomegalovirus (CMV) disease in patients receiving a renal transplant from a donor whose blood indicates a high likelihood of the presence of CMV.
Read the rest here:
Astellas, Vical herpes vaccine fails mid-stage study